P3 Health Partners price to book ratio PIII
Market value divided by the book value of the company's net assets, since 2023.
- Today, Oct 23, 2026
- 0.4×
- 3-year median
- 38.3×
- Against its 3-year history
- 0th
- percentile: 0 is its lowest day, 100 its highest
- 3-year range
- 0.4× to 117×
- Peer median
- 1.9×
P3 Health Partners' price to book ratio is 0.4× as of Oct 23, 2026.
That is below its 3-year median of 38.3×, lower than on 100% of days in the last 3 years.
Over that time it ranged from 0.4× in Oct 2026 to 117× in Dec 2023.
The median for 10 healthcare stocks of a similar size is 1.9×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 0.4× | 0.4× | 1.1× |
| 2025 | 1.3× | 0.7× | 43.7× |
| 2024 | 29.8× | 29.3× | 109× |
| 2023 | 117× | 85.8× | 117× |
Against its peers
Companies in Healthcare nearest P3 Health Partners' size, closest first, today.
| Company | Price to book ratio |
|---|---|
| PIIIP3 Health Partners | 0.4× |
| NEPHNephros | 3.2× |
| ATNMActinium Pharmaceuticals | 1.6× |
| APTAlpha Pro Tech | 0.9× |
| SPROSpero Therapeutics | 1.5× |
| LFVNLifevantage | 2.2× |
| ICCCImmucell | 3.0× |
| KEQUKewaunee Scientific | 1.3× |
| PDEXPro DEX | 4.2× |
| PLXProtalix BioTherapeutics | 2.9× |
| NATRNatures Sunshine Products | 1.3× |
| Peer median | 1.9× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on P3 Health Partners
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.